Natco Pharma Ltd
NSE:NATCOPHARM
US |
Fubotv Inc
NYSE:FUBO
|
Media
|
|
US |
Bank of America Corp
NYSE:BAC
|
Banking
|
|
US |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
|
US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
US |
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
|
CN |
NIO Inc
NYSE:NIO
|
Automobiles
|
|
US |
Fluor Corp
NYSE:FLR
|
Construction
|
|
US |
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
|
US |
TopBuild Corp
NYSE:BLD
|
Consumer products
|
|
US |
Abbott Laboratories
NYSE:ABT
|
Health Care
|
|
US |
Chevron Corp
NYSE:CVX
|
Energy
|
|
US |
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
|
US |
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
|
US |
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
|
US |
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
|
US |
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
756.3
1 592.85
|
Price Target |
|
We'll email you a reminder when the closing price reaches INR.
Choose the stock you wish to monitor with a price alert.
Fubotv Inc
NYSE:FUBO
|
US | |
Bank of America Corp
NYSE:BAC
|
US | |
Palantir Technologies Inc
NYSE:PLTR
|
US | |
C
|
C3.ai Inc
NYSE:AI
|
US |
Uber Technologies Inc
NYSE:UBER
|
US | |
NIO Inc
NYSE:NIO
|
CN | |
Fluor Corp
NYSE:FLR
|
US | |
Jacobs Engineering Group Inc
NYSE:J
|
US | |
TopBuild Corp
NYSE:BLD
|
US | |
Abbott Laboratories
NYSE:ABT
|
US | |
Chevron Corp
NYSE:CVX
|
US | |
Occidental Petroleum Corp
NYSE:OXY
|
US | |
Matrix Service Co
NASDAQ:MTRX
|
US | |
Automatic Data Processing Inc
NASDAQ:ADP
|
US | |
Qualcomm Inc
NASDAQ:QCOM
|
US | |
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one NATCOPHARM stock under the Base Case scenario is 681.5 INR. Compared to the current market price of 1 357.6 INR, Natco Pharma Ltd is Overvalued by 50%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Natco Pharma Ltd
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for NATCOPHARM cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
Natco Pharma Ltd
Balance Sheet Decomposition
Natco Pharma Ltd
Current Assets | 40.2B |
Cash & Short-Term Investments | 18.5B |
Receivables | 12B |
Other Current Assets | 9.8B |
Non-Current Assets | 28.8B |
Long-Term Investments | 1.4B |
PP&E | 24.4B |
Intangibles | 1.9B |
Other Non-Current Assets | 1.1B |
Current Liabilities | 9.7B |
Accounts Payable | 2.4B |
Short-Term Debt | 3.6B |
Other Current Liabilities | 3.7B |
Non-Current Liabilities | 804m |
Long-Term Debt | 53m |
Other Non-Current Liabilities | 751m |
Earnings Waterfall
Natco Pharma Ltd
Revenue
|
42.2B
INR
|
Cost of Revenue
|
-7B
INR
|
Gross Profit
|
35.2B
INR
|
Operating Expenses
|
-16.8B
INR
|
Operating Income
|
18.4B
INR
|
Other Expenses
|
-2B
INR
|
Net Income
|
16.4B
INR
|
Free Cash Flow Analysis
Natco Pharma Ltd
INR | |
Free Cash Flow | INR |
NATCO Pharma achieved consolidated revenue of INR 1,434.9 crores for Q2 FY '25, marking a 35.3% year-over-year growth. The net profit climbed 82% to INR 676.5 million, driven by strong export formulations and a stable domestic market. The company expects a 20% revenue growth for the coming year. Additionally, they declared an interim dividend of INR 1.5 per share. The market share for Revlimid is projected to capture one-third of the market by January, without anticipated challenges in this fiscal year.
What is Earnings Call?
NATCOPHARM Profitability Score
Profitability Due Diligence
Natco Pharma Ltd's profitability score is 70/100. The higher the profitability score, the more profitable the company is.
Score
Natco Pharma Ltd's profitability score is 70/100. The higher the profitability score, the more profitable the company is.
NATCOPHARM Solvency Score
Solvency Due Diligence
Natco Pharma Ltd's solvency score is 99/100. The higher the solvency score, the more solvent the company is.
Score
Natco Pharma Ltd's solvency score is 99/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
NATCOPHARM Price Targets Summary
Natco Pharma Ltd
According to Wall Street analysts, the average 1-year price target for NATCOPHARM is 1 284.59 INR with a low forecast of 696.9 INR and a high forecast of 1 758.75 INR.
Dividends
Current shareholder yield for NATCOPHARM is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Ownership
NATCOPHARM Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Profile
Country
Industry
Market Cap
Dividend Yield
Description
NATCO Pharma Ltd. engages in the business of pharmaceuticals with research, manufacturing and marketing of finished dosage formulations and active pharmaceutical ingredients. The company is headquartered in Hyderabad, Telangana. The firm is engaged in the development, manufacture and commercialization of complex pharmaceuticals catering to niche therapeutic areas. The firm deals in the production of finished dosage formulations (FDF), which it sells in India, the United States and the Rest of the World, as well as active pharmaceutical ingredients (APIs). Its capabilities include multi-step synthesis, semi-synthetic fusion technologies, production of high-potency APIs and peptides. The firm operates through two segments: pharmaceuticals and agrochemicals. The pharmaceuticals segment, the Company drives its sales through FDFs and APIs. The agrochemicals segment is focused on niche products, including pest management.
Contact
IPO
Employees
Officers
The intrinsic value of one NATCOPHARM stock under the Base Case scenario is 681.5 INR.
Compared to the current market price of 1 357.6 INR, Natco Pharma Ltd is Overvalued by 50%.